Figure 2
Figure 2. Threshold effect of CD79b cell-surface expression for in vitro efficacy and expression across lymphoma and leukemia. (A) CD79b-vcMMAE displays potent in vitro activity across NHL cell lines. and bars inidcate CD79b cell surface–negative and –positive cell lines, respectively. (B) Cell-surface expression is the primary predictor of response in vitro. (C) CD79b is broadly expressed across lymphomas and CLL. HCL indicates hairy cell leukemia; MZL, marginal zone lymphoma. (D) CD79b expression is maintained after relapse/progression from chemotherapy treatment in DLBCL (left panel) and FL (right panel). (E) CD79b expression is broadly expressed across DLBCL subtypes.

Threshold effect of CD79b cell-surface expression for in vitro efficacy and expression across lymphoma and leukemia. (A) CD79b-vcMMAE displays potent in vitro activity across NHL cell lines. and bars inidcate CD79b cell surface–negative and –positive cell lines, respectively. (B) Cell-surface expression is the primary predictor of response in vitro. (C) CD79b is broadly expressed across lymphomas and CLL. HCL indicates hairy cell leukemia; MZL, marginal zone lymphoma. (D) CD79b expression is maintained after relapse/progression from chemotherapy treatment in DLBCL (left panel) and FL (right panel). (E) CD79b expression is broadly expressed across DLBCL subtypes.

Close Modal

or Create an Account

Close Modal
Close Modal